衍生集團(06893.HK):雲浮市健康醫藥產業園獲確認為雲浮市首個國家3A級旅遊景區
格隆匯11月26日丨衍生集團(06893.HK)發佈公吿,集團的重點項目雲浮市健康醫藥產業園(簡稱“產業園”)獲得國家中醫藥管理局認可為“對港澳台中醫藥合作基地”,並獲雲浮市政府認可為“雲浮市愛國愛港實習基地”、“雲浮市科普教育基地”、“雲浮市中小學生研學實踐教育基地”、“雲浮市港澳台僑青少年創新創業交流實踐基地”及“雲浮市新的社會階層人士同心築夢實踐基地”。
此外,產業園也獲得中國文化和旅遊部正式確認為雲浮市首個國家3A級旅遊景區。產業園不僅是集團的生產廠房及研發中心,生產符合生產質量管理規範(GMP)要求的優質保健產品及食品,亦是推廣養生文化及藥食同源的國家級旅遊景點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.